PDF(Pubmed)
Abstract：
Pulmonary thromboendarterectomy (PTE) is the current gold standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH) and is a viable treatment option for chronic thromboembolic pulmonary disease (CTEPD). The progressive nature of both diseases severely impacts health-related quality of life (HRQoL) across a variety of domains. This systematic review was performed to evaluate the impact of PTE on short- and long-term HRQoL. A literature search was conducted on PubMed for studies matching the eligibility criteria between January 2000 and September 2022. OVID (MEDLINE), Google Scholar, EBSCOhost (EMBASE), and bibliographies of included studies were reviewed. Inclusion of studies was based on predetermined eligibility criteria. Quality appraisal and data tabulation were performed using predetermined forms. Results were synthesized by narrative review. The structure of this systematic review follows the PRISMA guidelines. This systematic review was prospectively registered in the PROSPERO register (CRD42022342144). Thirteen studies (2184 patients) were included. Within 3 months post-PTE, HRQoL improved in both CTEPD and CTEPH as measured by disease-specific and generic questionnaires. HRQoL improvements were sustained up to 5 years postoperatively in patients with CTEPH post-PTE. PTE remains the gold standard for treating CTEPH and improving HRQoL. Residual pulmonary hypertension and comorbidities such as COPD and coronary artery disease decrement HRQoL over time. The impact of mPAP and PVR on HRQoL outcomes postoperatively remain ambiguous. Pulmonary thromboendarterectomy remains the gold standard for treating CTEPH and has shown to improve HRQoL outcomes at 3-month sustaining improvements up to 5-year postoperatively. Residual pulmonary hypertension and comorbidities hinder HRQoL outcomes post-PTE.
摘要：
肺血栓内膜切除术（PTE）是当前慢性血栓栓塞性肺动脉高压（CTEPH）的黄金标准治疗方法，并且是慢性血栓栓塞性肺病（CTEPD）的可行治疗选择。这两种疾病的进行性性质严重影响了各个领域的健康相关生活质量（HRQoL）。这项系统评价旨在评估PTE对短期和长期HRQoL的影响。在PubMed上进行了文献检索，寻找符合2000年1月至2022年9月资格标准的研究。OVID(MEDLINE),谷歌学者，EBSCOhost(EMBASE),并对纳入研究的参考书目进行了综述。纳入研究是基于预定的资格标准。使用预定表格进行质量评估和数据制表。结果通过叙述性综述进行综合。本系统综述的结构遵循PRISMA指南。该系统评价预期在PROSPERO登记册(CRD42022342144)中注册。共纳入13项研究（2184例患者）。PTE后3个月内，通过疾病特异性和通用问卷测量，CTEPD和CTEPH的HRQoL均有所改善。PTE后CTEPH患者的HRQoL改善持续至术后5年。PTE仍然是治疗CTEPH和改善HRQoL的金标准。随着时间的推移，残留的肺动脉高压和COPD和冠状动脉疾病等合并症会降低HRQoL。mPAP和PVR对术后HRQoL结果的影响仍然不明确。肺血栓内膜切除术仍然是治疗CTEPH的金标准，并已显示在术后3个月持续改善至5年时可改善HRQoL结果。残余肺动脉高压和合并症阻碍PTE后HRQoL结果。
